Eslicarbazepine
| Evidence Level: L2 | Predicted Indications: 6 |
Table of Contents
Eslicarbazepine: From Epilepsy to Migraine Disorder
One-Sentence Summary
Eslicarbazepine (as eslicarbazepine acetate) is an antiseizure medication, and the US license records supplied do not list the approved indication text. The TxGNN model predicts it may be effective for migraine disorder, with 1 completed Phase 2 trial (452 participants, results not provided) and no directly supporting efficacy publications currently backing this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the license records (antiseizure medication, i.e. epilepsy) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L2 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the five listed are generic ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the Evidence Pack. Eslicarbazepine is generally understood to be a voltage-gated sodium channel blocker. Its efficacy in epilepsy is established, and mechanistically it may be applicable to migraine.
Epilepsy and migraine are both episodic disorders driven by neuronal hyperexcitability, and other antiseizure drugs are already used for migraine prevention. Reviews and genetic studies also describe shared genetic and molecular mechanisms between the two conditions, for example ion channel genes.
This link is plausible but indirect. The TxGNN score is a model prediction, not clinical proof.
Five other predictions have weaker support:
- Migraine with brainstem aura is a subtype with no subtype-specific evidence.
- Migraine susceptibility is a genetic label, not a treatable indication.
- Insomnia has only a pharmacovigilance signal of sleep disturbances with antiseizure drugs, which points away from benefit.
- Atrophoderma vermiculata and ulerythema ophryogenesis are rare skin disorders with no identified mechanistic link and no evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01820559 | Phase 2 | Completed | 452 | Double-blind, randomised, placebo-controlled study of eslicarbazepine acetate 800 mg/day or 1200 mg/day vs placebo (1:1:1) for migraine prevention, with or without aura. No efficacy or safety results are provided. |
A completed Phase 2 trial of this size that has not led to a Phase 3 program may suggest a lack of efficacy, but this is unconfirmed.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32217376 | 2020 | Review | J Neurol Sci | Tolerability and safety profile of eslicarbazepine acetate in neurological disorders |
| 38870050 | 2024 | Review | Expert Rev Neurother | Trigeminal neuralgia pharmacotherapy. Third-generation anticonvulsants and CGRP blockers for migraine are mentioned as possible options. |
| 35363878 | 2022 | Meta-analysis | Cochrane Database Syst Rev | Network meta-analysis of antiepileptic monotherapy in epilepsy (not migraine) |
| 25196459 | 2014 | Review | Expert Opin Drug Metab Toxicol | Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants |
| 22210279 | 2012 | Review | Adv Drug Deliv Rev | Chemical properties of antiepileptic drugs |
None of these publications reports efficacy of eslicarbazepine in migraine. The mechanistic literature on shared epilepsy–migraine biology (for example PMID 33856647) is listed under a related migraine label, not this indication.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA211227 | Eslicarbazepine acetate (Torrent Pharmaceuticals Limited) | Tablet | Not listed in the record |
| ANDA211186 | Eslicarbazepine acetate (Camber Pharmaceuticals, Inc.) | Tablet | Not listed in the record |
| ANDA211236 | Eslicarbazepine Acetate (Golden State Medical Supply, Inc.) | Tablet | Not listed in the record |
| ANDA211238 | Eslicarbazepine Acetate (Dr. Reddy’s Laboratories Inc) | Tablet | Not listed in the record |
All listed products are oral tablets. ANDA211227 appears twice in the source data and is shown once.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The only direct evidence is one completed Phase 2 migraine prevention trial whose results are not available. No Phase 3 follow-up is reported, and package insert safety data is missing. The mechanistic rationale is plausible but indirect, so the evidence is not yet enough to advance.
To proceed, the following is needed:
- The efficacy and safety outcomes of NCT01820559, from the registry results or a publication
- Package insert warnings and contraindications (blocking for safety screening)
- Formal mechanism of action data, for example from DrugBank
- The approved indication text for US licenses
- Drug interaction data, since none was found
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.